Benefits
Biological age reduction (Demidenko 2021 — small study)
Demidenko 2021 (PMC8660611) longitudinal observational study followed 42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months. AVERAGE 8-YEAR REDUCTION in biological age (TruAge DNA methylation test) over 7 months. Substantial effect size if real. CRITICAL CAVEATS: (1) self-reported, no placebo control, (2) single DNA methylation clock used, (3) selection bias possible, (4) small sample (n=42), (5) Ca-AKG combined with vitamins (cannot attribute to AKG alone). Hypothesis-generating, not confirmatory.
ABLE Phase 2 RCT ongoing
ABLE trial (NCT05706389, National University of Singapore Phase 2 RCT) testing Ca-AKG vs placebo for 6 months in 120 middle-aged adults (40-60 years) with biological age higher than chronological age. Primary outcome: biological age change. Will provide more rigorous evidence than Rejuvant observational study. Ongoing — results pending. Critical for definitively establishing or refuting biological age effects.
Animal lifespan extension across multiple species
AKG extends lifespan in fruit flies, C. elegans roundworms, and mice. Asadi Shahmirzadi 2020 mouse study showed Ca-AKG reduced frailty and enhanced longevity (compression of morbidity). Mechanism: caloric restriction mimetic via inhibiting ATP synthase and TOR, activating AMPK. Foundational preclinical evidence supporting human longevity research interest.
Bone density and strength support
Animal studies and limited human evidence suggest Ca-AKG supports bone density. Mechanism: stimulates collagen synthesis (proline hydroxylation requires AKG cofactor) and provides calcium for mineralization. Some human RCTs in osteoporosis showed bone marker improvements. Useful potential adjunct for skeletal health, particularly in older adults.
Wound healing and protein synthesis
Older clinical research showed AKG (often as ornithine α-ketoglutarate, OKG) improves nitrogen balance in surgical patients and burn victims. Improves wound healing and reduces protein catabolism. Mechanism via amino acid synthesis support and growth hormone secretion. Clinical use in some European hospitals as nutritional adjunct.
Muscle protein synthesis support (preclinical)
AKG provides nitrogen carriers for amino acid synthesis (transamination reactions), supporting muscle protein synthesis and reducing protein catabolism in stress states. Animal evidence supports anabolic effects; human translation in athletic/aging contexts is incomplete.
Mechanism of action
TCA cycle intermediate (energy metabolism)
AKG is one of eight TCA cycle intermediates — converted to succinyl-CoA via α-ketoglutarate dehydrogenase. Critical for glucose, fatty acid, and amino acid oxidation. Energy production substrate. Provides direct metabolic support for cellular energy demands.
Substrate for dioxygenases (epigenetic regulation)
AKG is required cofactor for 2-OG-dependent DIOXYGENASES — including TET enzymes (DNA demethylation), JmjC histone demethylases (chromatin modification), prolyl hydroxylases (collagen synthesis, HIF regulation), and many others. Supplementation may support epigenetic regulation — mechanism for biological age effects observed in Demidenko 2021.
Caloric restriction mimetic via ATP synthase / TOR / AMPK
Animal studies show AKG inhibits ATP synthase and TOR (target of rapamycin) signaling while activating AMPK pathway — mimicking effects of caloric restriction (the most reliable known longevity intervention in animals). Mechanism for lifespan extension observed in flies, worms, mice.
Glutamate-glutamine cycling and nitrogen metabolism
AKG combines with ammonia via glutamate dehydrogenase to form glutamate — central nitrogen disposal pathway. Used clinically (post-surgery) to manage nitrogen balance and support amino acid synthesis. Mechanism for protein-anabolic effects in catabolic states.
Calcium delivery (Ca-AKG specifically)
Ca-AKG salt provides BOTH alpha-ketoglutarate AND calcium — useful for bone health and as practical delivery mechanism. Calcium AKG enhances oral stability and bioavailability vs free AKG. Bone density benefits may relate to combined AKG + calcium effects rather than AKG alone.
Clinical trials
Longitudinal observational study (Demidenko O, Barardo D, Budovskii V, Finnemore R, Palmer FR 3rd, Kennedy BK, Budovskaya YV 2021, Aging 13(22):24485-24499, doi:10.18632/aging.203736, PMID 34847777). PMC8660611.
42 self-reported healthy individuals taking Rejuvant (sustained-release Ca-AKG + sex-specific vitamins) for 4-10 months. Biological age measured by TruAge DNA methylation test (Horvath-derived clock) before/during/after treatment.
Average 8-YEAR REDUCTION in biological age (TruAge DNA methylation) over average 7 months Rejuvant supplementation. Substantial effect if real. CRITICAL CAVEATS: (1) observational/uncontrolled design, no placebo, (2) self-reported subjects with potential selection bias, (3) single DNA methylation clock, (4) Rejuvant is combination product (AKG + vitamins), (5) sponsored by Ponce de Leon Health (commercial interest), (6) small sample. Most-cited human evidence for AKG biological age effects but methodologically limited.
Mouse longevity study (Asadi Shahmirzadi A, Edgar D, Liao CY, Hsu YM, Lucanic M, Asadi Shahmirzadi A, Wiley CD, Gan G, Kim DE, Kasler HG, Kuehnemann C, Kaplowitz B, Bhaumik D, Riley RR, Kennedy BK, Lithgow GJ 2020, Cell Metab 32(3):447-456.e6, doi:10.1016/j.cmet.2020.08.004).
C57BL/6 mice received Ca-AKG supplementation. Frailty, lifespan, and healthspan measured.
Ca-AKG REDUCED frailty and ENHANCED LONGEVITY in mice — compression of morbidity (mice lived longer AND with less age-related decline). Mechanism via inflammation reduction (reduced IL-6, IL-10) and improved healthspan markers. Foundational animal evidence supporting Ca-AKG's emergence as 'longevity supplement.' Critical mouse-to-human translation gap — animal lifespan studies do not reliably predict human supplementation effects.
Phase 2 randomized double-blind placebo-controlled trial (NCT05706389). National University of Singapore.
120 healthy middle-aged adults (40-60 years) with biological age higher than chronological age. Randomized to Ca-AKG or placebo for 6 months. Primary outcome: biological age change.
Currently ONGOING. Will provide more rigorous evidence than Demidenko 2021 observational study. Critical trial for the field — randomized placebo-controlled design with adequate sample size to detect biological age effects. Results pending. Independent of commercial Rejuvant sponsor. Important for definitively establishing or refuting Ca-AKG biological age effects.